logo
Share SHARE
FONT-SIZE Plus   Neg

AMAG Pharmaceutocals Reveal Positive Results From Phase III Study Of Feraheme

AMAG Pharmaceuticals Inc (AMAG) Wednesday announced positive preliminary results from the second phase III study for Feraheme in patients with iron deficiency anemia or IDA, regardless of the underlying cause.

The biopharmaceutical company stated that the study, called as IDA-301, compared Feraheme treatment to placebo and enrolled patients having IDA associated with various conditions including abnormal uterine bleeding, cancer, gastrointestinal disorders or other causes.

The company further stated that Feraheme demonstrated superiority on all primary efficacy endpoints evaluated in this study.

The company added that the efficacy and safety of Feraheme in this study were comparable to that reported in the IDA-302 study, the phase III IDA study comparing Feraheme to iron sucrose.

In the IDA-301 study, Feraheme demonstrated robust efficacy, achieving superiority on both primary efficacy endpoints. Patients treated with Feraheme achieved a statistically significant mean increase in hemoglobin at week five of 2.7 g/dL, compared to a mean increase of only 0.1 g/dL in patients who received placebo; importantly, these data are consistent with the 2.7 g/dL increase in hemoglobin reported in the IDA-302 study,

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Everyone knows that the Federal Reserve will raise interest rates next Wednesday at the conclusion of its two-day policy meeting. After all, Fed speakers have been jawboning a rate hike over the past few weeks. With the markets reacting with eerie calm to Donald Trump's win, policy makers have no... GOP strategist Karl Rove has criticized U.S. President-elect Donald Trump's comments on aircraft maker Boeing Co.'s contract for a new Air Force One plane, saying they were inaccurate and de-stabled the stock of a major company. Air Force One is the official air plane for the U.S. President. Elon Musk's space transport company SpaceX has lost a satellite launch order from one of its customers due to the delay in its rocket launch schedule after one of its rockets exploded in September.
comments powered by Disqus
Follow RTT